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Epidemiological data suggest that consumption of fruits and vegetables has been associated with a lower incidence of cancer. Cyanidin-3-glucoside (C3G), a compound found in blackberry and other
food products, was shown to possess chemopreventive and chemotherapeutic activity in the present study. In cultured JB6 cells, C3G
was able to scavenge ultraviolet B-induced 䡠OH and O2. radicals. In
vivo studies indicated that C3G treatment decreased the number of
non-malignant and malignant skin tumors per mouse induced by
12-O-tetradecanolyphorbol-13-acetate (TPA) in 7,12-dimethylbenz[a]anthracene-initiated mouse skin. Pretreatment of JB6 cells
with C3G inhibited UVB- and TPA-induced transactivation of
NF-B and AP-1 and expression of cyclooxygenase-2 and tumor
necrosis factor-␣. These inhibitory effects appear to be mediated
through the inhibition of MAPK activity. C3G also blocked TPAinduced neoplastic transformation in JB6 cells. In addition, C3G
inhibited proliferation of a human lung carcinoma cell line, A549.
Animal studies showed that C3G reduced the size of A549 tumor
xenograft growth and significantly inhibited metastasis in nude
mice. Mechanistic studies indicated that C3G inhibited migration
and invasion of A549 tumor cells. These finding demonstrate for the
first time that a purified compound of anthocyanin inhibits tumor
promoter-induced carcinogenesis and tumor metastasis in vivo.

Chemoprevention, the use of drugs or natural substances to retard or
reverse the process of carcinogenesis, represents one of several promising
strategies to reduce the development of cancer. Many naturally occurring
substances present in the human diet have been identified as potential chemopreventive and/or chemotherapeutic agents (1–3). A recent report published by the American Institute for Cancer Research regarding dietary
prevention of cancer indicates that ⬃7–31% of all cancers worldwide could
be reduced by diets high in fruits and vegetables (4, 5). Thus, searching for
novel natural agents and defining novel targets for chemoprevention have
become intense areas of investigation.
A recent study demonstrated that topical application of plant-derived
chemicals, such as caffeine or (⫺)-epigallocatechin gallate, inhibits carcinogenesis and selectively increases apoptosis in UVB2-treated mouse
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skin (6). Our previous study also indicated that fresh apple peel extract
exhibits anticarcinogenesis activity (7).
In a search for better chemopreventive or chemotherapeutic agents,
we isolated cyanidin-3-glucoside (C3G) from blackberries (8). C3G
belongs to the flavonoid class of molecules and is a member of the
anthocyanin family, the largest group of pigments present in many edible berries, dark grapes, cabbages, and other pigmented foods. Evidence
suggests that anthocyanins may serve as natural antioxidants (9).
Anthocyanins repair and protect genomic DNA integrity. Studies have
shown that berry anthocyanins are beneficial in reducing age-associated
oxidative stress, as well as in improving neuronal and cognitive brain
function. Early studies have shown that supplementations with berries
rich in anthocyanins were effective in reducing oxidative stress associated with aging, and were beneficial in reversing age-related neuronal
and behavioral changes (9, 10).
Over the past decades, extensive efforts have been made to develop
targeted therapies that can inhibit or prevent tumorigenesis. In this
regard, AP-1, NF-B, MAPKs, COX-2, and TNF␣ represent the most
promising pharmacological targets that have been identified (7, 11–13).
Activation of those targets/pathways has been shown to be involved in
tumor growth and development (14 –16).
Previous studies have reported that both AP-1 and NF-B are known
to be involved in transcriptional regulation of matrix metalloproteinase,
angiogenic enzymes that play an important role in malignant cancer
cells invasion and metastasis (17). AP-1 and NF-B also up-regulate the
expression of urokinase-type plasminogen activator (uPA) and its
receptor (uPAR). The inhibition of NF-B and AP-1 suppressed the
secretion of uPA, resulting in the inhibition of motility of highly invasive
breast cancer cells (18). Increased AP-1 activity is associated with malignant transformation and the action of cancer-promoting agents (15, 16).
Blocking TPA-induced AP-1 activation has been shown to inhibit neoplastic transformation (19). Moreover, a recent study using transgenic
mice has demonstrated that AP-1 transactivation is required for tumor
promotion (20).
COX-2 and TNF␣ are also important targets for modulating inflammation and carcinogenesis. TNF␣ inhibitors display a significant effect
in retarding inflammatory disease and carcinogenesis (21). COX-2, a
dimethylbenz[a]anthracene; AP-1, activator protein-1; COX-2, cyclooxygenase-2;
TNF␣, tumor necrosis factor ␣; NF-B, nuclear factor B; MAPK, mitogen-activated
protein kinase; MAPKK, MAPK kinase; ERK, extracellular signal-regulated kinase; JNK,
c-Jun N-terminal kinase; MKK4, MAP kinase kinase 4 (alternatively designated SEK1 or
MEK4); TPA, 12-O-tetradecanoylphorbol-13-acetate; FBS, fetal bovine serum; ROS,
reactive oxygen species; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type plasminogen activator receptor; CM-DCFDA, carboxymethyl dichlorofluorescein diacetate; PBS, phosphate-buffered saline; ABTS, 2,2⬘-aziodiethylbenzthiazoline sulfonate.

JOURNAL OF BIOLOGICAL CHEMISTRY

17359

Chemopreventive and Chemotherapeutic Effects of C3G
catalyst in prostaglandin synthesis from arachidonic acid, contributes to
the regulation of angiogenesis and metastasis (22, 23). Selective COX-2
inhibitors protect against the formation of tumors in animals, suggesting that prostaglandins, the products of COX-2 activity, substantially
contribute to carcinogenesis (24 –26). Overexpression of COX-2 is
common in human lung cancer and seems to be associated with tumor
progression, invasion, and metastasis. In experimental animal models,
COX-2 has been shown to be involved in tumor angiogenesis, suggesting that COX-2 is a potential target for cancer therapy. Several in vivo
studies have already shown that COX-2-specific inhibitors (celecoxib
and rofecoxib) have antitumor activity, and clinical trials using COX-2
inhibitors are currently ongoing in patients with lung caner (27, 28).
Reports focusing on mechanisms and in vivo data supporting the
possible chemopreventive and chemotherapeutic effects of purified
C3G are limited. In light of the important roles of NF-B, AP-1, COX-2,
TNF␣, and MAPK activation in carcinogenesis, we investigated the
potential ability of C3G to inhibit DMBA-TPA-induced skin papillomas
in animal skin model, suppress proliferation of tumor cells, suppress
tumor xenograft growth and metastasis in nude mice, down-regulate
NF-B, AP-1, and MAPK activities, down-regulate the expression of
COX-2 and TNF␣, and scavenge ROS generated in intact cells. The
results of this investigation provide new insights into the mechanisms
by which a natural antioxidant may control the production of ROSinduced activation of molecular signals involved in the initiation, promotion, and progression of cancer.

MATERIALS AND METHODS
Reagents—Eagle’s minimal essential medium was purchased from
Whittaker Biosciences (Walkersville, MD). FBS, gentamicin, and L-glutamine were from Invitrogen. Luciferase assay kit was obtained from
Promega (Madison, WI). PhosphoPlus MAPK antibody kits were purchased from New England Biolabs (Beverley, MA). Carboxymethyl
dichlorofluorescein diacetate and dihydroethidium were obtained from
Molecular Probes (Eugene, OR).
Cell Culture—The mouse JB6 cell line, which was stably transfected
with an AP-1, NF-B, COX-2, or TNF␣ luciferase reporter plasmid (18,
29, 30), was cultured in Eagle’s minimal essential medium containing 5%
FBS, 2 mM L-glutamine, and 50 g of gentamicin/ml. Human lung carcinoma cells, A549, were cultured in Dulbecco’s modified Eagle’s
medium containing 10% FBS. The cells were grown at 37 °C in a 5% CO2
atmosphere.
Isolation of C3G from Blackberries—High performance liquid chromatography was used to separate and isolate C3G from blackberry fruit
tissue. The detailed method for preparation of C3G has been described
elsewhere (8). Briefly, fruit samples were extracted twice with 80%
methanol and 0.01% HCl in a PolytronTM homogenizer for 1 min. The
concentrated extract was dissolved in acidified water (0.01% HCl) and
then passed through a C18 Sep-PakTM cartridge. C3G and other anthocyanins were adsorbed onto the column and then recovered from the
cartridge with acidified (0.01% HCl) methanol. The methanol extract
was passed through a 0.45-m membrane filter and further separated
by a Waters Corp. high performance liquid chromatography system
coupled with a photodiode array detector. The C3G-containing fraction
was collected, lyophilized, and stored at ⫺80 °C for later use. Isolation of
C3G as described by this method was 99% pure.
Assay of Total Antioxidant Capacity—The total antioxidant capacity
of C3G was determined using an ABTS (2,2⬘-aziodiethylbenzthiazoline
sulfonate) test set (Randox Laboratories Ltd., UK). The principle of the
assay depends on production of the radical cation ABTS⫹ in incubation
medium containing the substrates H2O2 and peroxidase. ABTS⫹ has a
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blue-green color, which can be detected at 600 nm. The assays were
calibrated against standards and expressed as micromoles per liter.
Cellular O2. and H2O2 Assay—Dihydroethidium and carboxymethyl
dichlorofluorescein diacetate (CM-DCFDA) are specific dyes used for
staining O2. and H2O2 produced by intact cells (31, 32). JB6 cells (2 ⫻
104/well) were seeded onto a glass coverslip in the bottom of a well of a
24-well plate for 24 h. The cells were pretreated with or without C3G for
30 min and exposed to UVB radiation (4 kJ/m2). At the end of the
stimulation, dihydroethidium or CM-DCFDA were added at a final
concentration of 5 M for 30 min. After the incubation, the cells were
washed with phosphate-buffered saline and mounted on coverslips. A
Zeiss LSM 510 microscope was used to obtain images. Scale bars were
generated and inserted by using LSM software.
Assay of AP-1, NF-B, COX-2, and TNF␣ Transcription/Promoter
Activity—A confluent monolayer of JB6 cells, which contained an AP-1,
NF-B, COX-2, or TNF␣ luciferase-reporter plasmid, was trypsinized,
and 5 ⫻ 104 viable cells were seeded in each well of a 24-well plate (18,
29, 30). The cells were then pretreated with C3G for 1 h followed by
exposure to TPA (20 ng/ml) or UVB radiation (4 kJ/m2) for 24 h. Then,
the effects on AP-1, NF-B, COX-2, and TNF␣ induction/expression
were monitored. Luciferase activity was measured using the luciferase
assay kit obtained from Promega as described previously (18).
Western Blot and Protein Kinase Phosphorylation Assay—Immunoblots for phosphorylation or expression of ERKs, JNKs, p38 kinase,
MEK4, and COX-2 proteins were carried out as described in the protocol from New England Biolabs, using the specific antibodies against
phosphorylated sites of ERKs, JNKs, p38 kinase, and MKK4. Anti-actin
antibody or non-phospho-specific antibodies provided in each assay kit
were used to normalize the phosphorylation assay by using the same
transferred membrane blot.
Animals and Two-stage Skin Carcinogenesis—Founder stocks for the
mice (C57BL/6 crossed with DBA2) used in this study were obtained
from the University of Minnesota (7). The mice were bred and housed in
the West Virginia University Animal Facility. The mice were monitored
free of specific pathogens housed in plastic filter-top cages on corncob
bedding, provided autoclaved tap water and Prolab 3500 feed ad libitum.
Both male and female mice (6 –9 weeks old) were used in groups numbering 19 to 24. Dorsal skin of the mice was shaved. A single dose of 400
nmol of 7,12-dimethylbenz[a]anthracene (DMBA) dissolved in 300 l
of acetone was applied. Two weeks following initiation, the mice (except
the negative control group) were promoted by dermal exposure to 17
nmol of TPA in 350 l of acetone twice a week for 21 weeks. For the
C3G-treated group, the dorsal skin was pretreated topically with C3G
(3.5 M/mouse) 30 min before each application of TPA. The negative
control group was treated with acetone only. The incidence of papillomas was detected by palpation, and the number of papillomas appearing
on each mouse was recorded once a week. At the end of the experiment,
all the animals were sacrificed by intraperitoneal injection of pentobarbital (6.5 mg/mouse). For histopathology, the largest tumors were
removed and fixed in freshly prepared 4% paraformaldehyde followed
by paraffin embedding and subjected to pathologic evaluation.
Anchorage-independent Transformation Assay—The inhibitory
effects of C3G on TPA-induced cell transformation were investigated in
JB6 cells. Cells (1 ⫻ 104) were suspended in 2 ml of 0.38% agar medium
over 3 ml of 0.5% agar medium containing 10% FBS, 20 ng/ml TPA with
or without C3G (5– 80 M). The cultures were maintained in a 37 °C, 5%
CO2 incubator for 14 days, and the anchorage-independent colonies
were scored by a computerized image analyzer.
Mouse Model Study for Tumor Xenograft Growth and Metastasis—
Male nu/nu homozygous nude mice (Crl: NU-Foxn1nu, 8 weeks old)
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purchased from Charles River Laboratories Inc. (Wilmington, MA).
The mice were grouped in 10 mice per group and housed in autoclaved
plastic filter-top cages and were provided with autoclaved tap water and
Prolab 3500 feed ad libitum. Human lung carcinoma cells, A549, were
harvested from tissue culture and subcutaneously injected (2 ⫻ 106
cells/flank) in both the right and left flanks of each mouse to initiate
tumor growth. Two days after cell implantation, the mice were treated
intraperitoneal with either PBS or C3G dissolved in PBS (9.5 mg/kg, 3
times/week). Once tumor xenografts started growing, their sizes were
determined by measuring tumor size with calipers twice weekly in two
dimensions throughout the study. The tumor volume was calculated by
the formula, 0.5236 ⫻ L1 ⫻ (L2)2, where L1 is the long diameter and L2
is the short diameter. The tumor volume (mm3) is represented as the
mean of 10 mice in each group.
Transwell Cell Migration Assay—The assay was performed according to the methods described previously (31). The cells were serumstarved overnight, and the Transwells were coated with enhanced
chemiluminescence cell attachment matrix (Upstate Biotechnology) at
20 g/ml. The top chambers of the Transwells were loaded with 0.2 ml
of cells (4 ⫻ 105cells/ml) in serum-free media, and the bottom chambers
contained 0.6 ml of Dulbecco’s modified Eagle’s medium with 0.5% FCS.
The cells were incubated in Transwells at 37 °C in 5% CO2 in the presence or absence of C3G for 12 h. Migrating cells were fixed and stained
with 0.1% crystal violet, followed by dye elution. The microplate reader
was used to measure the optical density of the eluted solutions to determine the migration values.
Wound Healing Assay—The wound healing assays were conducted
according to the methods described previously (32). A549 cells were
grown on coverslips to 100% confluent monolayer and then scratched to
form a 100-m “wound” using sterile pipette tips. The cells were then
cultured in the presence or absence of C3G in serum-free media for 12 h
and fixed on coverslips with 4% formalin. The images were recorded
using an Olympus photomicroscope.
Cell Invasion Assay—The cell invasion assays were performed
according to the methods described previously (32). A549 cells were
cultured in serum-free media overnight. The cells (5 ⫻ 104 cells) were
loaded on pre-coated Matrigel 24-well invasion chambers (BD Biosciences) in the presence or absence of C3G. Then 0.5 ml of 5% fetal calf
serum medium was added to the wells of the plate to serve as the chemoattractant for the cells. The Matrigel invasion chambers were incubated for 18 h. The invading cells were fixed with 10% formalin, stained
with Harris modified hematoxylin (Fisher), and analyzed according to
manufacturer’s instructions.
Statistics—Data presented are the means ⫾ S.E. of n assays as noted
in the figure legends. Significant differences were determined using the
Student’s t test. Significance was set at p ⱕ 0.05.

RESULTS
Total Antioxidant Capacity of C3G—ROS have been known to be
associated with many diseases. ROS are associated not only with initiation, but also with promotion and progression in the multistage carcinogenesis mode (33, 34). In light of the important role of ROS in tumor
promoter-induced AP-1 activation, transformation, and progression,
we measured the total antioxidant capacity of C3G using the Randox
reagent set. As show in Fig. 1A, C3G displayed a stronger antioxidant
activity than that of ascorbic acid over the same concentration range,
suggesting that C3G can effectively scavenge ROS.
Scavenging of H2O2 and O2. Generation by C3G—To confirm the
ROS-scavenging activity of C3G, the effect of C3G on UVB-induced
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FIGURE 1. A, total antioxidant capacity of C3G. The total antioxidant capacity of C3G and
ascorbic acid was determined as described under “Materials and Methods.” The results
were calculated as total antioxidant capacity and presented as mmol/l. B and C, confocal
micrograph of inhibitory effect of C3G on UVB-induced O2. and H2O2 generation. JB6 cells
were pretreated with C3G at indicated concentration and then exposed to UVB. After
staining by dihydroethidium or CM-DCFDA, the images were captured with a laser scanning confocal microscope. The bright greenish areas in the cells represent oxidized
CM-H2-DCFDA, and the bright reddish spots represent oxidized dihydroethidium showing the intracellular localization of H2O2 (B) and O2. (C), respectively.

H2O2 and O2. generated in intact cells was tested. H2O2 and O2.
generation was analyzed using intracellular staining by CM-H2DCFDA and dihydroethidium. CM-H2-DCFDA is a specific fluorescent dye for H2O2, and dihydroethidium is specific for O2. . JB6 cells
were pretreated with or without C3G for 30 min and then exposed to
UVB (4 kj/m2). The generation of H2O2 and O2. was monitored by
confocal microscopy. As shown in Fig. 1 (B and C), the generation of
H2O2 and O2. by UVB was completely inhibited by addition of C3G at
20 M and 40 M, respectively.
Inhibition of AP-1, NF-B, COX-2, and TNF␣ Activation/Expression
by C3G—Previous studies have shown that AP-1, NF-B, COX-2, and
TNF␣ play an important role in carcinogenesis (7, 20, 21, 28). We tested
the effects of C3G on UVB- and TPA-induced transactivation of AP-1
and NF-B, and expression of COX-2 and TNF␣ using a reporter gene
assay in JB6 cells. The results indicated that pretreatment of the cells
with various concentrations of C3G produced a dose-dependent
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FIGURE 2. Effects of C3G on UVB- and TPA-induced AP-1, NF-B, COX-2, TNF␣, and MAPK activation/expression. The JB6 cells, which were stably transfected with the AP-1,
NF-B, COX-2, or TNF␣ luciferase reporter plasmid, were pretreated with C3G for 1 h followed by exposure with TPA (20 ng/ml) or UVB radiation (4 kJ/m2) for 24 h. The relative AP-1
(A) and NF- B (B) activity, and the relative COX-2 (C) and TNF␣ expression (D) were measured by the luciferase assay. Results, presented as relative activity/expression compared with
untreated control cells, are given as means ⫾ S.E. from three assay wells. The experiment was repeated three times. *, significant increase from untreated negative control.
**, significant decrease from the positive control. The effect of C3G on COX-2 expression was also confirmed by Western blot assay (lower panel of C).

decrease in AP-1, NF-B, COX-2, and TNF␣ activity/expression
induced by either UVB irradiation or TPA (Fig. 2, A–D). The induction
of COX-2 expression was confirmed by Western blot analysis (Fig. 2C,
bottom panel). The inhibitory actions of C3G were not caused by cyto-
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toxicity, because the concentration range that inhibited AP-1, NF-B,
COX-2, and TNF␣ activity/expression did not affect cell proliferation as
measured by the electric cell-substrate impedance sensor assay (data
not shown).
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FIGURE 2.—continued

FIGURE 3. Effect of C3G on MAPK and MKK4 activation. JB6 cells were treated as
described under “Materials and Methods.” MAPKs (A) and its upstream regulator MKK4
(B) activation were analyzed by Western blot with phospho-specific antibodies against
phosphorylated sites. One representative blot of three or four experiments is shown.

C3G Blocks UVB- and TPA-induced p38, ERK, and JNK Phosphorylation—Because C3G showed an inhibitory effect on AP-1, NF-B,
COX-2, and TNF␣ activity/expression, we further investigated the
effects of C3G on MAPK pathways. MAPK pathways, including ERK,
JNK, and p38 kinase, are involved in up-regulation of AP-1 and NF-B
activity and subsequence expression of TNF␣ and COX-2 by increasing
the abundance of the components and/or altering the phosphorylation
of their subunits (35, 36). The results indicated that C3G suppressed
UVB- and TPA-induced phosphorylation of p38, ERK, and JNK (Fig.
3A), as well as the upstream regulator, MKK4 (Fig. 3B), in a dose-dependent manner. These results suggest that the mechanism by which
C3G inhibits AP-1 transactivation may involve early inhibition of ERK,
JNK, and p38 signaling cascades.
C3G Inhibits TPA-induced JB6 Cell Transformation—Earlier studies
have indicated that AP-1 and/or NF-B activation is required in neo-
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plastic transformation and tumorigenesis in JB6 cells (19, 20). We thus
tested the effect of C3G on TPA-induced cell transformation using the
soft agar assay. The result is shown in Fig. 4A. TPA-induced cell transformation was significantly inhibited by C3G at the concentration range
from 10 to 40 M. At the concentration of 80 M C3G, the TPA-induced
transformation was completely abolished.
Inhibition of Papillomagenesis and Malignant Transformation by
C3G—To further study the antitumorigenic activity of C3G in vivo, we
evaluated the effect of C3G on the two-stage mouse skin tumor model in
which DMBA was used as initiator and TPA as promoter (37, 38). Fourteen days following DMBA initiation, the dorsal skin of the mice was
exposed to TPA in the presence or absence of C3G three times per week
to cause promotion. The results show that treatment of the animals with
C3G decreased the number of tumors per mouse at all exposure times
(Fig. 4B). Significant differences were observed 17 weeks after TPA promotion. The maximum number of papillomas after 20 weeks of TPA
exposure in the C3G-treated mice was 1.59 ⫾ 0.65 per mouse compared
with 3.57 ⫾ 1.06 papillomas per mouse in the positive control group,
indicating a greater than 53% inhibition of papillomagenesis by C3G. In
addition to the difference in the numbers of tumors, the size of tumors
was smaller in the C3G-treated group. Two representative mice from
each group showing the greatest number of papillomas are shown in Fig.
4C. Tumors in the positive control group grew rapidly and were well
vascularized, whereas tumors in the C3G-treated group appeared
growth-arrested and desiccated. After 22 weeks, there were four tumors
greater than 4 –5 mm in diameter in the TPA-treated group, whereas no
large tumors were found in the C3G plus TPA-treated group. Histological analysis indicated that those large tumors were squamous cell carcinomas (data not shown). These data suggest that C3G plays an important role in preventing malignant conversion.
Effect of C3G on Proliferation of Human Lung Cancer Cells in Vitro—
To further investigate the antitumor activity of C3G, the effects of C3G
on proliferation of A549 cells, a human lung carcinoma cell line, were
evaluated by using an electric cell-substrate impedance sensor assay. As
shown in Fig. 5A, C3G dramatically inhibited proliferation of A549 in a
dose-dependent manner. At the concentration of 40 M, the growth of
tumor cells was completely blocked.
Inhibitory Effect of C3G on Tumor Growth in Mice—We further
tested the in vivo effect of C3G on xenograft growth of A549 cells in
athymic male nude mice. A549 cells were injected subcutaneously in
both right and left flanks of each mouse to initiate tumor growth. Ani-
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FIGURE 4. Effect of C3G on TPA-induced cell
transformation and tumorigenesis in DMBA/
TPA-treated mice. A, JB6 P⫹ cells (1 ⫻ 104) were
exposed to TPA (20 g/ml) with or without the
indicated concentrations of C3G on soft agar
medium for 14 days. The cell colonies were scored
by a computerized image analyzer. *, significant
increase from untreated negative control. **, significant decrease from the positive control. B, skin
tumors were generated by DMBA and TPA treatment as described under “Materials and Methods.” The number of papillomas was recorded
weekly. The results are presented as the mean of
papillomas per mouse ⫾ S.E. of 21–26 mice. *, a
significant difference in the number of papillomas
between the positive control group and the C3G
treated group (p ⱕ 0.05). C, external appearance
of tumors. Two mice from the positive control
group (left) and C3G-treated group (right) showing the greatest number of tumors are shown. The
arrow indicates a tumor ⬎5 mm in diameter.

mals were treated intraperitoneally with either PBS or C3G (9.5 mg/kg)
three times per week beginning 2 days after the tumor cell implantation.
As shown in Fig. 5B, tumor size showed a significant reduction in the
C3G-treated group (⬃50% inhibition) compared with the PBS-treated
control group. This result indicates that C3G treatment inhibited tumor
growth in athymic nude mice.
C3G Suppresses Tumor Cell Metastasis in Mice—The effect of C3G
on tumor metastasis dissemination into other organs was evaluated by
macroscopic and microscopic examination of tissue sections. Pathological analysis indicated that the mice in the positive control group show a
large subcutaneous tumor mass at the site of injection, and the tumors
invaded through the abdominal wall and extended into the abdominal
cavity, resulting in peritoneal carcinomatosis (Fig. 6A). Multiple small
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tumor nodules were observed on the peritoneal surface of the abdominal wall (Fig. 6A). The tumor also was extensively involved with the
mesenteric fat with malignant ascites (Fig. 6B). Tumor involvement was
not only present on the surface but also within the parenchyma of
organs, such as liver, kidney, pancreas, and perigastric lymph nodes
(Table 1). In contrast, the C3G-treated mice showed much less tumor
involvement of the abdominal cavity, although a smaller subcutaneous
tumor mass at the injection site was observed. Fewer tumor nodules
were observed in the abdominal cavity and the mesenteric fat. There
was no tumor detected in organ parenchyma in the C3G-treated mice.
Microscopically, positive control mice show a large subcutaneous
tumor mass at the site of injection (Fig. 6C), whereas the injection site of
the C3G-treated mice showed collections of macrophages with pig-
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FIGURE 5. Suppression of proliferation and
tumor growth of human lung carcinoma cells
by C3G in vitro and in vivo. A, A549 cells were
incubated in electrode array wells with or without
C3G at the indicated concentration for 72 h. The
electric cell-substrate impedance sensor resistance, indicating the cell growth, was monitored
for the duration of the experiment. Data shown
are representative of three independent experiments. Cells in serum-free (Serum-) medium were
used as a negative control. B, male nude mice
aged 8 weeks were used. A549 cells (2 ⫻ 106/flank)
were subcutaneously implanted into both right
and left flanks of each mouse to initiate tumor
growth. The mice were treated intraperitoneally
with either PBS or C3G. Once tumor xenografts
started growing, their size was measured twice
weekly in two dimensions throughout the study.
Tumor volume (mm3) was calculated by the formula width2 ⫻ length ⫻ 0.52. Each value represents the mean ⫾ S.E. of 10 mice. *, a significant
difference from the positive control (p ⬍ 0.02).

ment, consistent with phagocytosis of pigment derived from the C3G
compound. There were viable tumor cells in the deep skeletal muscle
distant from the subcutaneous injection site. These results suggest that
subcutaneous administrations of C3G not only inhibited A549 cells
xenograft growth but also prevented metastasis.
Inhibitory Effects of C3G on Cancer Cell Migration and Invasion—Because cancer cell migration and invasion are the key events in metastasis, we further tested the effects of C3G on cell migration and invasion
in vitro. Our results showed that C3G significantly blocked A549 cell
migration in both wound healing assays (Fig. 7A) and Transwell assays
(Fig. 7B). The potency of inhibition for cell migration was 25% at 40 M
of C3G and 70% at 80 M of C3G in the Transwell assays (Fig. 7B). C3G
was also able to inhibit cell invasion in a dose-dependent manner, 57% at
40 M and 85% at 80 M, as measured by Matrigel invasion assays (Fig.
7C). These results are consistent with the in vivo animal study, demonstrating that C3G may have the ability to inhibit cancer cell migration
and invasion and prevent metastasis.

DISCUSSION
Chemoprevention, the use of drugs or natural substances to inhibit
carcinogenesis, is an important and rapidly evolving aspect of cancer
research that is providing a practical approach to identify potentially
useful inhibitors of cancer development. Anthocyanins are a group of
naturally occurring phenolic compounds related to the coloring of
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plants, flowers, and fruits and recently have been reported to be as
potential cancer preventive agents (10). There is increasing interest in
the pharmacological activity of anthocyanins, and C3G is a major member of anthocyanins (10, 39 – 41). In blackberry extract, C3G represents
⬃80% of the total anthocyanins (10). Herein we report the chemopreventive and chemotherapeutic potential of C3G using in vitro and
in vivo studies. The results from this study identify C3G as representing
a novel compound with potent activity against a solid tumor cell growth
and metastasis in vivo. Topical application of C3G prior to TPA application inhibits the formation of keratoacanthomas and squamous cell
carcinomas in the mouse skin model. The molecular pathways involved
in anticarcinogenesis by C3G were also investigated.
AP-1 and NF-B are transcription factors that have been implicated
in a wide range of cell biological events, including cell proliferation,
inflammation, differentiation, metastasis, and apoptosis. Inhibition of
AP-1 and NF-B activation by a variety of agents has been shown to
reduce neoplastic transformation (19). In vivo studies in transgenic mice
indicate that AP-1 transactivation is required for tumor promotion (20).
The blockade of TPA-induced cell transformation and tumorigenesis in
the mouse skin model by C3G might be through the inhibition of AP-1
and NF-B activity. Therefore, the inhibitory effects of C3G on AP-1
and NF-B activation noted in this study suggest a potential beneficial
role in preventing carcinogenesis in vivo.
MAPKs, including ERK, JNK, and p38 MAPK, are activated in

JOURNAL OF BIOLOGICAL CHEMISTRY

17365

Chemopreventive and Chemotherapeutic Effects of C3G

FIGURE 6. Macroscopic and microscopic findings of tumor metastases from an implanted
human lung carcinoma in nude mice. A, in the
positive control mouse, the tumor invaded
through the abdominal wall and extended into
the abdominal cavity, resulting in peritoneal carcinomatosis (arrow on left panel). In contrast, the
C3G-treated mice showed no tumor involvement
at the abdominal wall (left panel). B, in the positive
control mouse, the tumor also extensively
involved the mesenteric fat with malignant ascites (arrows). C, sections of implanted tumor from
dorsal skin of positive control mouse (left) and
C3G treated mouse (right) at 5 weeks after tumor
inoculation. Tumor from positive control mouse
shows aggressive growth at the injection site. In
contrast, tumor from C3G-treated mouse shows
less aggressive growth, and the injection site
shows a collection of macrophages with pigment
at a higher magnification (right bottom panel) consistent with the phagocytosed pigment derived
from the C3G compound. There are viable tumor
cells in the deep skeletal muscle distant from the
subcutaneous injection site.

TABLE 1
Inhibitory effect of C3G on metastasis
Number of mice

a

Treatment

Peritoneal
metastasis

Other parenchyma organs
(liver, kidney, pancreas) metastasis

PBS
C3G

8 (80)a
2 (20)

4 (40)
0

Numbers in parentheses are percent.

response to environmental stresses and growth factors. Studies indicate that ERK, JNK, and p38 kinase are key molecules activated in
response to oxidant injury. Both UVB and TPA can induce ROS
generation in the cells (36, 42– 44). AP-1 is a downstream target of
these three MAPKs. We found that C3G could scavenge UVB-inducted ROS in JB6 cells and inhibit UVB- and TPA-induced phosphorylation of ERK, JNK, and p38 kinase. These observations suggest
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that these inhibitory effects on AP-1 and MAPK activation with C3G
may be due to its antioxidant properties.
Angiogenesis is essential for tumor growth in vivo (45). Angiogenesis
is a complex process where several proteins and enzymatic pathways
converge. COX-2 contributes to the regulation of angiogenesis by various genes, including platelet-derived growth factor and transforming
growth factor-␤ (46). Overexpression of COX-2 is common in nonsmall cell lung cancer and seems to be associated with tumor progression, invasion, and metastasis (47). Several in vivo studies have already
shown that COX-2-specific inhibitors (celecoxib and rofecoxib) have
antitumor activity (27, 48). The inhibitory effect of C3G on COX-2
expression may contribute to the suppression of human lung carcinoma
growth.
Tumor invasion and metastasis are multistep and complex processes
that include cell division and proliferation, proteolytic digestion of the
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demonstrated that MAPKs, including JNK, p38, and ERK, play crucial roles in cell migration. JNK, for example, regulates cell migration
by phosphorylating paxillin, Jun, and microtubule-associated proteins. Studies of p38 show that this MAPK modulates migration by
phosphorylating MAPK-activated protein kinase 2/3, which appears
to be important for directionality of migration. ERK governs cell
movement by phosphorylating myosin light chain kinase, calpain, or
focal adhesion kinase. Therefore, the different kinases in the MAPK
family all seem able to regulate cell migration but by distinct mechanisms (49, 54). Thus, the inhibitory effects of C3G on AP-1, MAPK,
NF-B, and COX-2 may contribute to the suppression of tumor cell
growth and metastasis in nude mice.
In conclusion, we have demonstrated that the phytochemical C3G
exhibits chemoprevention and chemotherapeutic activities in experimental animals, possibly by interfering with signal transduction molecular, including AP-1, MAPK, NF-B, COX-2, and TNF␣, through its
ROS scavenger capacity. These data suggest that C3G may function as a
potential anticancer agent with little cytotoxicity to normal tissue. Thus,
C3G merits further investigation as a cancer therapeutic and preventive
agent in humans. These studies establish a promising area of investigation in understanding the molecular mechanisms responsible for the
beneficial effects of phytochemicals on human health.
Acknowledgment—We thank Dr. Peilin Zhang for expert assistance with
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